A Flow Capacity Of Over 1.3 Billion Vaccine Market Leading Enterprise Price High - A Flu Vaccine -

Temple of Heaven Hualan Biological become the second thing was after the production

of influenza H1N1 SFDA approval Influenza Virus Vaccine drug certificate of domestic listed companies.

States since September 4 release of influenza vaccine purchasing and storage scheme, a huge flow up the concept of plate harvest, biological products segment rose 20% composition range, in which leading companies Hualan increase biological objects and the Temple of Heaven were 39% and 36%, while the A shares rose 8%.

Analysts believe that a flu vaccine market is expected to capacity during the year will exceed 1.3 billion, but the vaccine has generally been leading the company's stock price high.

Considerable profits for vaccine production Recently, the Ministry of Health will be completed before the National Day 1% of the total population of reserves, that is, 13 million of the scale, a flow capacity of the vaccine market, at least more than 260 million yuan. September 4, the Ministry of Industry and Beijing Sinovac and Hualan material were issued to complete the first batch of influenza vaccine 3.3 million and 4 million of production tasks.

Analysts predict a flu vaccine purchasing and storage prices are likely low, but a vaccination margins will not be lower than that influenza vaccine is expected to around 60%. Currently the price of ordinary flu vaccine 20-30 yuan / agent between this price performance of listed companies can estimate the degree of thickening.

For Hualan matter, the only country to honor the current vaccine 4 million orders, 15% of the income tax deduction, the company will be more than 40 million yuan net profit. Companies to disclose, before the National Day, will produce 13 million of influenza vaccine, if these vaccines are given the national reserve, the company will receive about 130 million yuan of net profit. This calculation, the company earnings per share is expected to thickening of 0.36 yuan.

Bank of China International researcher Zhou Mingjie that Hualan objects larger vaccine production capacity is expected to reduce costs through scale advantages, gross margin is likely higher, with the company's vaccine products may be exported to foreign countries, the company's actual earnings are a new increment.

Nevertheless, the current stock valuations have been high. In accordance with 15 closing price of 57.89 yuan to the operator, Hualan material price-earnings ratio more than 40 times.

Market value of more than 1.3 billion yuan

Autumn has been the spread of influenza has increased the speed. 14 Ministry of Health informed, at 15 o'clock on the September 11 to at 15 o'clock on the September 14 three days time, a flow of Mainland China's 1598 cases of confirmed cases, 14 cases of foreign imported cases, 1584 cases of infection for the territory cases.

With the spread of influenza throughout the acceleration in the state purchasing and storage capacity is expected to increase further.

8 21, Health Minister Chen Zhu said that the mainland this year by the end of Influenza H1N1 influenza vaccine production to meet demand for 5% of the population. According to China's 1.3 billion population, the first batch of vaccine purchasing and storage at about 65 million goal. This is considered a flu vaccine production this year, the bottom line, which means that influenza vaccine this year, the market capacity will not be less than 1.3 billion.

Influenza vaccine coverage of China's population is lower than in many foreign countries, the United States released more than 60% the proportion of Japan is 42%, it is likely to increase the purchasing and storage capacity of influenza to cover more population. During the year the industry is generally expected to upgrade to 1.3 Collection and storage target more likely hundreds of millions more doses.

In addition to these four companies have received approval other than influenza vaccine, a vaccination or other six companies in the state under review, expected to be recently obtained production approval. Hualan recently developed materials have been completed influenza vaccine clinical research, is expected to influenza vaccine production capacity will further increase.

by: gaga

POST COMMENT

Bodylastics Reviews - Can It Be The Fifty Dollar Secret Alternative To Bowflex? Herbs For Depression Are Used By Patients Worldwide Nfl Belly Rings: Body Jewelry Of A Different Kind Symptoms Of BV and Some Remedies To Treat It Medical Symptoms Diagnosis Of Alzheimer's Disease DBS for Parkinson's Disease also cure OCD The Health Benefits Of Coconut Oil Electronic cigarette have flavor? Now Is The Time To Seek A Mesothelioma Picture If You've Been Experiencing Mesothelioma Symptoms A Study of Electronic Cigarette Could Someone Else Be Responsible For Your Mesothelioma Symptoms? Useful Information About Electronic Cigarettes Rapid Fat Loss: Healthy Weight Loss for Kids